Group 1 - Tong Ren Tang's Executive Vice President Zhang Chunyou submitted a resignation letter, effective July 8, 2025, due to work adjustments, while remaining as General Manager of Tong Ren Tang Technology [1] - The company stated that Zhang Chunyou's departure will not adversely affect daily operations, indicating limited market impact from this internal personnel adjustment [1] Group 2 - Basestone Pharmaceuticals announced an exclusive strategic partnership with Istituto Gentili for the commercialization of Sugliant in Western Europe and the UK, granting Gentili exclusive rights in 23 countries [2] - Basestone will receive up to $192.5 million in payments, including upfront, registration, and sales milestone payments, along with nearly 50% revenue sharing from net sales in the authorized region [2] - This collaboration enhances Basestone's international market recognition and strengthens investor confidence in future growth [2] Group 3 - Fosun Pharma announced guarantees for its subsidiaries, providing a maximum joint liability guarantee for a financing application not exceeding 500 million yuan with Bank of China [3] - Additionally, a guarantee was provided for a financing contract not exceeding 150 million yuan with China Construction Bank for its subsidiary Hanlin Pharmaceutical [3] - This move supports subsidiaries in obtaining funds for business expansion or R&D, although it introduces certain financial risks [3] Group 4 - Run Da Medical responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, addressing issues related to operating performance, goodwill, short-term solvency, and prepayments [4] - The response aims to alleviate market concerns and stabilize investor confidence, although ongoing monitoring of the company's performance improvement measures is necessary [4] Group 5 - Yuan Da Pharmaceutical announced that its joint venture Sirtex Medical Pty Ltd received FDA approval for SIR-Spheres Yttrium-90 microspheres for treating unresectable hepatocellular carcinoma (HCC) [5] - This product is the first and only FDA-approved selective internal radiation therapy for both unresectable HCC and colorectal cancer liver metastases [5] - This breakthrough enhances Yuan Da's market position in oncology and boosts investor confidence in future growth [5]

Policy Developments - Abbott Molecular Inc. has initiated a recall of its automated real-time fluorescent nucleic acid amplification analysis system due to design defects [1] - Other companies including Ortho Clinical Diagnostics, Leica Biosystems, Beckman Coulter, and Aesculap have also recalled products due to various issues such as potential bias in reportable range, incorrect labeling, cross-contamination, and rising complaint trends [1] Drug and Device Approvals - Jianyou Co., Ltd. has received FDA approval for the production site transfer of its Idarubicin Hydrochloride Injection in multiple dosages [2] - Xinhua Pharmaceutical has been granted approval for the listing of Eicosapentaenoic Acid Ethyl Ester as a chemical raw material drug [3] Capital Market Activities - Guangzhou Pharmaceutical, a subsidiary of Baiyunshan, will be listed on the New Third Board starting May 20, 2025 [4] - Chuangxin International has completed nearly 100 million RMB in Series B financing led by Yueke Fund and Zhongshan Haochuang Fund [5] Industry Events - Kanghui Pharmaceutical has won a first-instance judgment in a lawsuit against Kelewei Biopharmaceuticals regarding equity repurchase, requiring Kelewei to pay 2 million RMB in deposit and 35.994 million RMB in repurchase funds [6] - Weigao Blood Purification Products Co., Ltd. has officially listed on the Shanghai Stock Exchange, raising approximately 1.09 billion RMB through its IPO [7] Public Sentiment Alerts - Sanleaf Bio has changed its accounting firm due to disagreements over audit fees [8] Management Changes - Dize Pharmaceutical's executives plan to reduce their shareholdings due to personal financial needs, with specific amounts detailed for each individual [9][10] - Jia Ying Pharmaceutical's CFO has resigned for personal reasons and will no longer hold any position within the company [11]